Trump says tariffs on South Korean autos, pharma, to rise to 25% over trade deal approval delay
Seoul's Auto and Pharma Giants Face Steep Tariff Threat Amid Trade Deal Delays
President-elect Trump's proposed 25% tariffs on South Korean imports signal a tougher stance on trade, directly linking market access to foreign policy approval. This move could significantly reshape import dynamics and supply chains for investors.
Investors should monitor official responses from Seoul and potential retaliatory measures to gauge the trade conflict's true trajectory.
Key Takeaways
- 1The proposed 25% tariff would target South Korea's critical automotive and pharmaceutical exports to the United States.
- 2The move is explicitly tied to frustrations over delays in South Korea's formal approval of adjusted trade deal terms.
- 3South Korean automakers Hyundai and Kia are particularly vulnerable given their significant export volumes to the U.S. market compared to local production capacity.
- 4This escalation signals a shift toward sector-specific tariffs to achieve broader diplomatic and legislative goals within the KORUS FTA framework.
President-elect Trump’s threat to impose 25% tariffs on South Korean automotive and pharmaceutical imports represents a significant escalation in trade protectionism, targeting the United States' sixth-largest trading partner. This move is specifically framed as a response to delays in the domestic approval of bilateral trade amendments, signaling a 'transactional' approach to foreign policy. For investors, the automotive sector faces the most immediate risk; South Korean giants Hyundai and Kia have aggressively expanded their U.S. market share, and a 25% levy would likely force a choice between absorbing margin compression or raising prices, which would erode competitiveness against domestic U.S. manufacturers. The inclusion of pharmaceuticals marks a broader scope than previous trade skirmishes, potentially disrupting the supply chain for biosimilars and contract manufacturing where Korean firms like Samsung Biologics and Celltrion are global leaders. Historically, such rhetoric has served as a toolkit for negotiation, but the specific mention of the 25% figure suggests a high baseline for upcoming talks. Market participants should monitor official responses from Seoul and potential retaliatory measures that could impact U.S. tech exports to Korea, particularly specialized semiconductor equipment.